Apollomics (APLM) Stock

FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced Company management will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference taking place on September 9-11, 2024 virtually and in person at the Lotte New York Palace Hotel in New York, NY.

FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced financial results for the first half of 2024 ended June 30, 2024, and highlighted updates for its pipeline.

FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, announced today that it received written notification from The Nasdaq Stock Market LLC (“Nasdaq”) that it has granted the Company's request for a 180-day extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market. As previously disclosed, Apollomics had received a notice from Nasdaq on January 16, 2024 that it is not in compliance with the Bid Price Requirement (as defined below), because the closing bid price of the Company's Ordinary Shares was below $1.00 per share for 30 consecutive business days.

Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need

Apollomics (NASDAQ: APLM ) stock is rising higher on Friday as the shares bounce back on recent study results. Those study results cover the “efficacy response of a patient treated with vebreltinib for GBM with PTPRZ-MET fusion.

Apollomics is a small company with a pipeline of c-Met targeting small molecule TKIs for various cancers. Their lead candidate, Vebreltinib, is in phase 2 trials for NSCLC, GBM, and other solid tumors. They also have a second asset, APL-106, which is a specific E-Selectin antagonist being explored as a therapeutic target in certain types of cancer metastasis.

Some of the most promising penny stocks are up-and-coming and just just getting started. The world of penny stocks is all about speculating which young firms have the potential to become the next big companies.